Change in platelet count as a prognostic indicator for response to primary tyrosine kinase inhibitor therapy in metastatic renal cell carcinoma.
about
Early response of C-reactive protein as a predictor of survival in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors.PD-L1 is expressed on human platelets and is affected by immune checkpoint therapy.Tyrosine Kinase Inhibitor Pazopanib Inhibits Platelet Procoagulant Activity in Renal Cell Carcinoma Patients
P2860
Change in platelet count as a prognostic indicator for response to primary tyrosine kinase inhibitor therapy in metastatic renal cell carcinoma.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
2016年學術文章
@zh
2016年學術文章
@zh-hant
name
Change in platelet count as a ...... tastatic renal cell carcinoma.
@en
type
label
Change in platelet count as a ...... tastatic renal cell carcinoma.
@en
prefLabel
Change in platelet count as a ...... tastatic renal cell carcinoma.
@en
P2093
P2860
P356
P1433
P1476
Change in platelet count as a ...... tastatic renal cell carcinoma.
@en
P2093
Alp T Beksac
Brian R Lane
Christopher J Kane
Conrad Tobert
Frederick Millard
Ithaar H Derweesh
James M Randall
Juan Jimenez
P2860
P304
P356
10.1111/BJU.13490
P577
2016-03-24T00:00:00Z